Agios Pharmaceuticals Announces Board and Compensation Changes
Ticker: AGIO · Form: 8-K · Filed: Jul 8, 2025 · CIK: 1439222
| Field | Detail |
|---|---|
| Company | Agios Pharmaceuticals, Inc. (AGIO) |
| Form Type | 8-K |
| Filed Date | Jul 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
Related Tickers: AGIO
TL;DR
Agios Pharma (AGIO) filed an 8-K on July 3rd about board and exec comp changes.
AI Summary
On July 3, 2025, Agios Pharmaceuticals, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indicates a shift in leadership and potential adjustments to how key personnel are compensated.
Why It Matters
Changes in a company's board and executive compensation can signal strategic shifts or governance adjustments that may impact future performance and investor confidence.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can sometimes precede significant strategic shifts or indicate internal dynamics that warrant closer investor scrutiny.
Key Numbers
- 001-36014 — SEC File Number (Identifies the company's filing with the SEC.)
- 20250703 — Report Date (Earliest date of events reported in the 8-K filing.)
Key Players & Entities
- Agios Pharmaceuticals, Inc. (company) — Registrant
- July 3, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 88 Sidney Street, Cambridge, MA 02139 (address) — Principal Executive Offices
- 001-36014 (filing_id) — SEC File Number
FAQ
What specific changes were made to the board of directors?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors', but the specific names and details of the changes are not provided in this excerpt.
What are the details of the new compensatory arrangements?
The filing mentions 'Compensatory Arrangements of Certain Officers' but does not provide specific details on the nature or value of these arrangements in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on July 3, 2025.
What is Agios Pharmaceuticals, Inc.'s principal executive office address?
Agios Pharmaceuticals, Inc.'s principal executive office is located at 88 Sidney Street, Cambridge, MA 02139.
What is the company's SEC file number?
The company's SEC file number is 001-36014.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 8, 2025 regarding AGIOS PHARMACEUTICALS, INC. (AGIO).